Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.
Herein we describe the case of a patient with primary diffuse leptomeningeal gliomatosis (PDLG). After surgery and ventriculoperitoneal shunt placement, due to poor general conditions, the patient was not eligible for radiotherapy. For this reason we decided to start a systemic chemotherapy treatment with Temozolomide (150 mg/m2 per day for 5 days every 4 weeks). After three cycles a partial response was achieved with a clear improvement of general conditions. In our knowledge, this is the first time that PDLG treatment with Temozolomide has been described.
Franceschi
Enrico
E
Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, 40139, Italy.
Cavallo
Giovanna
G
Scopece
Luciano
L
Esposti
Roberta Degli
RD
Paioli
Gabriele
G
Paioli
Anna
A
Palmerini
Emanuela
E
Foschini
Maria Pia
MP
Marliani
Anna Federica
AF
Crinò
Lucio
L
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide